Q2 EPS Estimate for Soleno Therapeutics Lifted by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for Soleno Therapeutics in a research note issued to investors on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $1.00 per share for the quarter, up from their previous estimate of $0.85. HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q3 2026 earnings at $1.24 EPS and Q4 2026 earnings at $1.70 EPS.

Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group set a $125.00 price objective on shares of Soleno Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 7th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $114.00 price target (up from $106.00) on shares of Soleno Therapeutics in a research note on Tuesday. Zacks Research upgraded Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Buy” and an average target price of $110.62.

Soleno Therapeutics Stock Down 0.4%

Shares of NASDAQ SLNO opened at $43.56 on Wednesday. The company has a quick ratio of 15.88, a current ratio of 16.08 and a debt-to-equity ratio of 0.10. The firm has a market cap of $2.34 billion, a PE ratio of -23.67 and a beta of -3.12. The company’s fifty day simple moving average is $47.32 and its 200 day simple moving average is $61.69. Soleno Therapeutics has a 12-month low of $39.43 and a 12-month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.39. The company had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SLNO. Vanguard Group Inc. raised its position in Soleno Therapeutics by 12.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,807,149 shares of the company’s stock valued at $189,763,000 after buying an additional 319,317 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Soleno Therapeutics by 25.7% during the third quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock valued at $174,258,000 after purchasing an additional 527,777 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Soleno Therapeutics by 272.3% during the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock worth $156,298,000 after purchasing an additional 1,691,057 shares during the last quarter. Invesco Ltd. grew its position in Soleno Therapeutics by 132.3% in the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock worth $101,435,000 after purchasing an additional 854,551 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its position in Soleno Therapeutics by 18.0% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,429,756 shares of the company’s stock worth $119,785,000 after purchasing an additional 218,511 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.